Table 5.
Safety-evaluable patients∗ | Control (n = 32), N (%) | Intervention (n = 32), N (%) |
---|---|---|
Serious adverse events | 0 | 0 |
Epigastric pain | 0 | 1 (3.12) |
Abdominal pain | 2 (6.24) | 1 (3.12) |
Constipation | 2 (6.24) | 0 |
Xerostomia | 4 (12.5) | 0 |
Dizziness | 2 (6.25) | 0 |
Total number of adverse events | 10 (31.25) | 2 (6.24) |
Total number of subjects experiencing adverse events∗∗ | 6 (18.75) | 2 (6.24) |
∗ includes all patients who received at least one dose of study medication. ∗∗P value = 0.12. Control: hyoscine; intervention: herbal medicine.